Cargando…

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

BACKGROUND: Pulmonary hypertension (PH) is a life-threatening disease with poor prognosis. Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib. CASE PRESENTATION: Here, we disc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hennigs, Jan K, Keller, Gunhild, Baumann, Hans Jörg, Honecker, Friedemann, Kluge, Stefan, Bokemeyer, Carsten, Brümmendorf, Tim H, Klose, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121732/ https://www.ncbi.nlm.nih.gov/pubmed/21605451 http://dx.doi.org/10.1186/1471-2466-11-30

Ejemplares similares

N-Terminal Pro-Brain Natriuretic Peptide Is a Useful Prognostic Marker in Patients with Pre-Capillary Pulmonary Hypertension and Renal Insufficiency
por: Harbaum, Lars, et al.
Publicado: (2014)

Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer
por: Hennigs, Jan K., et al.
Publicado: (2020)

Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors
por: Balabanov, Stefan, et al.
Publicado: (2013)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

Low intensity, long-term outpatient rehabilitation in COPD: a randomised controlled trial
por: Baumann, Hans Jörg, et al.
Publicado: (2012)

Aaptamines from the Marine Sponge Aaptos sp. Display Anticancer Activities in Human Cancer Cell Lines and Modulate AP-1-, NF-κB-, and p53-Dependent Transcriptional Activity in Mouse JB6 Cl41 Cells
por: Dyshlovoy, Sergey A., et al.
Publicado: (2014)

Fiber optic bronchoscopy in patients with acute hypoxemic respiratory failure requiring noninvasive ventilation - a feasibility study
por: Baumann, Hans Jörg, et al.
Publicado: (2011)

Acute effects of exercise on the inflammatory state in patients with idiopathic pulmonary arterial hypertension
por: Harbaum, Lars, et al.
Publicado: (2016)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro
por: Balabanov, Stefan, et al.
Publicado: (2011)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension
por: Hennigs, Jan K., et al.
Publicado: (2014)

Organbezogene Folgeerscheinungen von COVID‑19 bei Erwachsenen
por: Hennigs, Jan K., et al.
Publicado: (2022)

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
por: Chang, Q, et al.
Publicado: (2008)

Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
por: Saladi, Venkata Narasayya, et al.
Publicado: (2022)

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
por: Gu, Yue, et al.
Publicado: (2023)

5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells
por: Oing, Christoph, et al.
Publicado: (2018)

The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells
por: Borriello, Adriana, et al.
Publicado: (2011)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
por: Rodríguez-Agustín, Andrea, et al.
Publicado: (2023)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
por: Barbarin, Alice, et al.
Publicado: (2020)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

Micro-RNA expression in cisplatin resistant germ cell tumor cell lines
por: Port, Matthias, et al.
Publicado: (2011)

Genetic evidence for a causative effect of airflow obstruction on left ventricular filling: a Mendelian randomisation study
por: Harbaum, Lars, et al.
Publicado: (2021)

Respiratory muscle dysfunction in long-COVID patients
por: Hennigs, Jan K., et al.
Publicado: (2022)

Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension
por: Fazakas, Csilla, et al.
Publicado: (2018)

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
por: Xiao, Xinhua, et al.
Publicado: (2020)

Dasatinib-induced Pulmonary Hypertension
por: Tamura, Yudai, et al.
Publicado: (2022)

Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension
por: Harbaum, Lars, et al.
Publicado: (2017)

Mycalamide A Shows Cytotoxic Properties and Prevents EGF-Induced Neoplastic Transformation through Inhibition of Nuclear Factors
por: Dyshlovoy, Sergey A., et al.
Publicado: (2012)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole
por: Yuan, Yuting, et al.
Publicado: (2023)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential
por: Körbelin, Jakob, et al.
Publicado: (2023)

Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension
por: Ostermann, Jonna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uodabpqtonfijbln47q4qqnmq5